Despite its potential, the integration of 3D bioprinting with AI in cancer research and treatment faces several challenges. One major issue is the complexity of accurately replicating the tumor microenvironment. Additionally, the scalability of these technologies remains a concern, as producing large quantities of bioprinted tissues can be resource-intensive. There are also regulatory hurdles to overcome, as the clinical application of bioprinted tissues requires thorough validation and approval from health authorities.
